The NF1 gene revisited -from bench to bedside

• Main Authors: Yap, Y.-S, McPherson, J.R, Ong, C.-K, Rozen, S.G, Teh, B.-T, Lee, A.S.G, Callen, D.F
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: Impact Journals LLC 2020
• Subjects: 2 (2 chloro 4 iodoanilino) n cyclopropylmethoxy 3,4 difluorobenzamide; alisertib; alpha2a interferon; erlotinib; everolimus; imatinib; isotretinoin; n (2,3 dihydroxypropoxy) 3,4 difluoro 2 (2 fluoro 4 iodoanilino)benzamide; neurofibromin; pirfenidone; placebo; rapamycin; retaspimycin; selumetinib; sorafenib; thalidomide; tipifarnib; article; brain tumor; breast tumor; cancer inhibition; colorectal carcinoma; down regulation; drug potentiation; drug targeting; epigenetics; gene deletion; gene mutation; gene sequence; genetic association; genetic procedures; hematologic malignancy; human; lung cancer; malignant peripheral nerve sheath tumor; melanoma; molecular diagnosis; neurofibroma; neurofibromatosis; next generation sequencing; NF1 gene; nonhuman; ovary carcinoma; phase 1 clinical trial (topic); phase 2 clinical trial (topic); protein function; somatic mutation; tumor suppressor gene; animal; genetics; neoplasm; Animals; Genes, Neurofibromatosis 1; Humans; Neoplasms; Neurofibromin 1
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174999
• Institution: National University of Singapore

10.18632/oncotarget.2194